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Summary Parameters characterising the progression of cervical neoplasia were estimated from population-
based cancer and mortality statistics in Sweden for 1958-1981 by means of a dynamic computer model.
Proceeding from that model and these data, the incidence and prevalence curves were constructed, the effects
of the extensive cytological screening measures introduced during the 1960s were assessed, and future gains
due to the measures already undertaken up to 1981 could be simulated. About 4,000 cases of cancer in situ
were diagnosed annually in Sweden after the end of the 1960s, most of them in women born later than 1919.
The maximum reduction in the number of invasive cancers up to 1981 was 42% for women born in
1919-1923, but increased progressively for later birth cohorts and reached 69% for those born in 1934-1938.
The corresponding reduction in mortality rates was of the same magnitude. The screening measures up to 1981
will ultimately result in a reduction of invasive cancer by about 12,500 cases and of the number of deaths due
to this disease by about 4,100. Only a part of the total gain in the number of lives saved had been revealed at
the end of the study period in 1981.
The absence of randomised trials has hampered valid assess-
ment of the effectiveness of screening for cervical cancer over
a long period of time. Less powerful, although ultimately
convincing, evidence that early detection and treatment of
pre-invasive cancers result in decreasing morbidity and mor-
tality has been obtained from cross-sectional and cohort data
referring to the periods before and after the onset of screen-
ing measures (Day, 1984; Hakama et al., 1985; Pettersson et
al., 1985; Miller, 1986; Laara et al., 1987; Lynge et al., 1989)
and from case-control studies (Clarke & Anderson, 1979;
Macgregor et al., 1985; Geirsson et al., 1986; IARC, 1986).
Mathematical modelling and computer simulation has also
been used during the last decade to elucidate the natural
history of cervical neoplasia and to quantify the effect of
screening (Knox, 1976; Habbema et al., 1983; Parkin &
Moss, 1986; Prorok, 1986). The results have been equivocal,
however (Prorok, 1986), and have aroused only limited atten-
tion in the medical community.
Vague ideas about the natural history of cervical neoplasia
have also impeded the evaluation of screening measures and
the design of cost-effective screening strategies (Hakama et
al., 1985; Knox, 1982). A recent collaborative study from the
International Agency for Research on Cancer (IARC, 1986)
did, however, elucidate the natural history of cancer of the
cervix from the screening viewpoint, and provide quantitative
estimates of screening effects. We used an entirely different
modelling approach which confirmed the IARC estimates in
the Swedish data and assessed past benefit. In a recent study
we were able to describe the natural history of cervical
neoplasia (Gustafsson & Adami, 1989). This work was made
possible by the availability in Sweden of reliable population-
based registers which provide the annual number of detected
cases of in situ and invasive cancer of the cervix as well as the
annual mortality rates for this disease since 1958. The exten-
sive cytological screening measures that were introduced in
Sweden in the late 1960s caused a profound disturbance of
the system through the detection and cure of a large number
of cases of cancer in situ (and preclinical invasive cancers) of
the cervix.
Proceeding from a dynamic compartmental model which
describes the natural history ofcervical cancer as a sequential
process of tumor progression, we were able to characterise
each stage in terms of transition times and probabilities. A
consistent model was thus produced with mutual com-
patibility between structure - including the states of and the
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flows between healthy, cancer in situ, invasive cancer and
death - statistics and parameters (Gustafsson & Adami,
1989).
The aim of the present study was to assess from a national
perspective the effects ofcytological screening in terms of the
reduction in the number of cases of invasive cancer of the
cervix and in the number of deaths due to this disease. The
parameter values obtained in the foregoing investigation
(Gustafsson & Adami, 1989) were applied to the model of
the natural history ofcervical neoplasia in simulation studies.
We were thus able to calculate the changes in prevalence and
incidence rates of in situ and invasive cancer following
cytological screening, and the gains due to screening up to
1981, and also to estimate the future gain of the measures
undertaken so far.
Material and methods
Cytological screening
Screening for cancer of the uterine cervix takes two major
forms in Sweden, namely organised screening programmes
and smears taken as part of other health care activities or in
routine medical care, Together these efforts will be referred
to in the following as 'screening measures'. Organised screen-
ing, with invitations to all women aged 30-49 years every 4
years, was introduced successively from 1964 and was being
carried out in 13 out of 26 counties in Sweden by the end of
1967. After a recommendation from the National Board of
Health and Welfare that year, screening started in 12 addi-
tional counties during the following 3 years and in the last
one in 1977 (Pettersson et al., 1985; National Board of
Health and Welfare, 1982).
The estimated total annual number of smears increased
from 200,000 in 1963 to about one million in 1970. One
decade later, about 250,000 out of 1.1 million smears per
year were from the organised screening programme and the
remaining 850,000 from outpatient care, birth control
activities, antenatal clinics and so on (Pettersson et al., 1985;
National Board of Health and Welfare, 1982). Nearly com-
plete coverage of the target population was thus achieved
(Hakama et al., 1985). A study in three Swedish counties
revealed that during the period 1971-1981, 95% of all
women born in 1932-1951 had at least one smear taken and
71% had three smears. Among women born in 1922-1931,
the corresponding figures were 88 and 53% respectively,
whereas considerably lower figures were found for older birth
cohorts (Stenkvist et al., 1984). As a result of these
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endeavours, large numbers of cases of cancer in situ of the
cervix were diagnosed, particularly in the younger birth
cohorts (Figure 1). In this study as well as in the foregoing
(Gustafsson & Adami, 1989), the number of in situ cases is
the input, whereas the number of smears and other screening
conditions fall outside the scope of this study and are only
discussed above as a background.
Morbidity and mortality statistics
The National Swedish Cancer Registry was initiated in 1958
(Cancer Incidence, 1960-1984). All physicians in hospitals
and other establishments for medical treatment under public
administration, and all pathologists and cytologists, are
required to submit separate reports to the Registry on every
diagnosis of malignant disease made on clinical grounds or
on the basis of examination of surgically removed tissues,
biopsy specimens, cytology specimens or autopsy findings.
This obligation to report also includes precancerous lesions
classified as cancer in situ of the uterine cervix or more
specifically from 'cancer in situ portio-cervices (and such
severe dysplasia which are on the border of cancer in situ)'
(National Board of Health and Welfare, 1968). The propor-
tion of such borderline cases among those reported as cancer
in situ by the Swedish Cancer Registry is unknown.
In 95% of the cases, the Registry thus receives notification
from both the physician and the pathologist. The Registry
therefore includes virtually all cases of malignant disease in
the entire Swedish population, and the proportion of
unreported cases of cancer in the female genital tract has
been estimated to be less than 1% (Mattsson & Wallgren,
1984). Swedish population-based incidence (National Board
of Health and Welfare, 1982) and mortality statistics (Statis-
tics Sweden) are published annually and will be referred to as
'reported' rates in the following text.
The use of registry data entails a pragmatic definition of
the neoplastic lesions analysed in this context. Cancer in situ
and invasive cancer thus refer to cases that were actually
reported to the Registry or would have been detected and
reported if subjected to a cytological screening examination.
The impact of possible differences in criteria for classification
between pathologists and cytologists could thus not be
analysed. Likewise, screening effects on the prevalence of
borderline lesions other than those reported as cancer in situ
could not be included in the analysis.
Model structure
The time evolution of cervical cancer proceeds from the state
of being healthy via cancer in situ and invasive cancer to
death. Between succesive states (prevalences) there are flows
(incidences). This sequence of progression of the disease is
the main evolution. In situ cases may regress or progress, or
they may be discovered by screening and removed. Of the
diagnosed invasive cases a certain proportion can also be
cured.
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Figure 1 Annual age-specific rate ofdiagnosed cases of cancer in
situ for different birth cohorts during 1958-1981. Consecutive
5-year birth cohorts age denoted I (born in 1939-43) to 8
(1904- 1908).
In the case of no screening, a progressive disease will
usually be diagnosed in its invasive stage, which is thereby
divided into the pre-diagnosis phase and the post-diagnosis
one, during which the woman is a patient and can be fol-
lowed. This conceptual model was elaborated into the
dynamic compartmental model presented in Figure 2. The
prevalences or states are cancer in situ, preclinical invasive
and clinical invasive. These states change only as a result of
the incidences or flows. We have, therefore, an integrated
model in which the states are represented by numbers of
cases which vary with time and the flows are numbers of
cases per year, also varying with time. The flows 'in situ
incidence', and 'invasive incidence' in Figure 2 will be
denoted 'true incidence' in the following text and were
estimated by identification (see below), whereas 'Diagnosis
and removal of in situ cases' in Figure 2 is denoted 'reported
incidence'.
The way in which screening measures affect the whole
system is evident from Figure 2. The cancer in situ cases
found by screening measures (known from statistics) are
subtracted from the in situ box, resulting in a subsequently
reduced flow of diagnoses of invasive cancer which is lagging
and dispersed in time. Still later the disturbance will also
reach the mortality flow.
Identification
From the statistics (National Board of Health and Welfare,
1960-84; Statistics Sweden, 1960-83), a calculation was made
of the age-specific cohort time series for the flows of diagnoses
of invasive cancer and of mortality. The model describes the
same behaviour provided that we use the correct set of
parameters and a correct function for the age-specific
incidence of cancer in situ. Estimation of the set of
parameters and the in situ function that give the best fit
between model and statistics is called parameter estimation
and is one type of identification. The identification process
was more comprehensively discussed recently (Gustafsson &
Adami, 1989) and the methodology was described in detail in
a separate monograph (Gustafsson, 1986).
The identification process was performed on eight different
5-year birth cohorts born between 1904 and 1943 during the
24-year period 1958-1981. As an example, the results for the
cohort born in 1924-1928 are shown in Figure 3. The
parameters and the age function of true in situ cases were
estimated to give the best least square fit between model
result and statistics. The upper part of Figure 3 shows the
true and true minus reported incidence of in situ cases and
the lower part the statistics (2B, 3B) and model output (2C,
3C) for the incidences of new diagnoses of invasive cancer
and of mortality.
As a result of the identification study (Gustafsson &
Adami, 1989), a dynamic model, in which the parameters and
the function of new in situ cases was estimated, was achieved.
From this model all incidences and prevalances as functions
of age could be obtained for the eight birth-cohorts and the
effects of the screening measures could be calculated. Finally,
the model was simulated beyond the year 1981 to estimate
the future effects of screening measures up to 1981.
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Figure 2 The natural history of cervical neoplasia as a compart-
mental model.
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Figure 3 Results of identification for the cohort born in 1924-28.
IA denotes the true and IB the true minus reported incidence rate
of cancer in situ. 2 denotes the incidence of invasive cancer given as
reported rates without (A) and with (B) impact ofscreening, and as
model output (C). 3 denotes mortality, given as reported rates
without (A) and with (B) impact of screening and as model outputs
and as model outputs (C).
Results
Incidence and mortality rates with and without screening
The estimated results of screening are illustrated in Figure 4
for the five most screened of the studied 5-year birth cohorts.
The reference (reported) invasive incidence and mortality
rates based on the period 1958-1967 and the true age-
specific incidence curve for cancer in situ were based on
previous analyses (Gustafsson & Adami, 1989). The stippled
areas of the upper parts of Figure 4a-e show the eliminated
number of in situ cases for each cohort. The lower parts
present both the reported incidence and mortality rates and
the rates derived from model outputs. Note that the statis-
tical values and model outputs coincide closely both for
reported incidence rates of invasive cancer and for mortality
rates.
From the diagrams it is seen that the impact of screening
actions was considerable for cohorts born after 1919 (Figure
4). These actions had only marginal effects in older cohorts
(not shown). Among the extensively screened cohorts a large
decrease was found both in the number of diagnoses of
invasive cancer and in the number of deaths per year.
The total gain up to 1981 is shown as stippled areas
between the respective curves in Figure 4. In Table I the
average reductions from screening during the five last years
1977-1981 are presented. This reveals reductions of between
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Figure 4 Annual reported age-specific incidence and mortality
rates without screening (reference values for 1958- 1967) and with
screening, given as statistical values and model outputs for
different cohorts, born (a) 1939-43, (b) 1934-38, (c) 1929-33,
(d) 1924-28 and (e) 1919-23. For notations, see Figure 3.
TableI Theeffectsofscreening measuresup to 1981,given aspercentage reduction inthe
reported incidence of invasive cancer and in mortality for different birth cohorts.
Reduction in reported incidence (%) Reduction in mortality (%)
Cohort born 1977-81' Maximal (year)b 1981 1977-81a Maximal (year)b 1981
1939-43 58 61 66 68
1934-38 68 69 66 71
1929-33 67 67 (1979) 67 59 63
1924-28 56 56 (1978) 54 48 52
1919-23 40 42 (1978) 38 23 27 (1976) 19
aMean reduction during the period 1977-1981. bResults shown only when the
maximum reduction occurred before 1981.
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50 and 70% in reported invasive incidence and mortality
among women born later than 1924. In the younger cohorts
the annual reductions in the reported incidence and mortality
was still on the rise in 1981. The reduction in mortality was
of the same magnitude as that in incidence, although the
effects of screening were delayed in time. For women born
before 1918 the effects of screening were small and could not
be reliably calculated.
Prevalence rates with and without screening
The prevalence rates of undiagnosed cancer in situ and
invasive cancer are functions of the flows to and from these
states (Figure 2). They are thus dependent, for example, on
the rate ofprogression from in situ to preclinical invasive and
from preclinical to clinical invasive cancer, respectively.
Another important determinant is the diagnostic intensity,
i.e. the magnitude and timing of the exposure to screening.
The age-specific prevalence rates of cancer in situ only and
together with preclinical invasive cancer with and without
screening are shown for successive 5-year birth cohorts born
in 1919-1943 in Figure Sa-e. Without screening (the
reference curves A and B), the age-specific prevalence of
cancer in situ reaches a peak of about 3.5% at the age of 35
years and decreases to about half that value at the age of 55.
The corresponding curve for invasive cases shows a maxi-
mum of 0.16% at the age of about 45 years, or 10 years after
the prevalence peak of cancer in situ (not shown).
The prevalence curve of cancer in situ cases over age for
the case without screening (curve A in Figure Sa-e) was also
compared to corresponding results from a 'prevalence screen-
ing'. In Swedish statistics investigations for the years 1967
(9,000 women) and 1968 (51,000 women) were found
(National Board of Health and Welfare, 1970). Unfortun-
ately, these findings were classified in Papanicolaou I-V and
not as cancer in situ. However, using assessments of cancer in
situ from Papanicolaous in the same publication, it was
possible to obtain a sketch of detection over age for 1967 and
1968. This showed a peak rate of 2.3 and 3.8% for the age
interval 30-35 years to be compared to our estimated
prevalence of 3.5% at 35 years. The prevalence curve A in
Figure 5 agrees rather well with the statistics mentioned
above.
The shapes of the curves were fairly accurately computed,
as was the prevalence rate of cancer in situ. The estimated
prevalence of the undiagnosed invasive cases is, however, less
reliable, because the magnitude is proportional to the time
constant of the preclinical phase of invasive cancers and this
parameter was calculated with fairly poor accuracy as
3.9± 1.9 years (Gustafsson & Adami, 1989).
The exposure to screening has drastically influenced the
prevalence rates of both cancer in situ and preclinical invasive
cancer. As seen in Figure 5, the prevalence of in situ cancer
was reduced by up to about 50% for some of the birth
cohorts. The corresponding reduction of preclinical invasive
cancer was still larger (not shown). This pattern, with large
numbers of in situ lesions detected at an early age in the
younger birth cohorts (Figure 1), reflects the combined
effects of the differing age at the start, the differing extent of
exposure to cytological screening among the cohorts, and the
rapidly increasing incidence of cancer in situ to a maximum
at the age of 30, with a considerable decrease during the
following decades (Gustafsson & Adami, 1989).
Predicted totalgain due to screening up to 1981
By continuing the simulation beyond 1981, an estimate could
be made of the total gain from the screening measures under-
taken up to 1981, when these effects had become completely manifest. An example of such a simulation is shown in
Figure 6 for the cohort born in 1924-1928. Translation of
these rates to the real number of women has to take into
account the decreasing size of the cohorts due to intercurrent
mortality. As seen in Figure 6, only about half of the total
reduction of invasive cases was manifest in 1981 for the
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Figure 5 Estimated age-specific prevalence rates of in situ and
preclinical invasive cervical cancer with and without screening for
different birth cohorts born (a) 1939-43, (b) 1934-38, (c)
1929-33, (d) 1924-28, and (e) 1919-23. A and C denote the
prevalence of in situ cancer without and with screening, respec-
tively. B and D denote the sum of the prevalence rates ( in situ
plus undiagnosed invasive cases) without and with screening
respectively.
cohort born in 1924-1928, whereas an even greater part of
the mortality reduction would emerge after that period of
time.
During the years 1958-1981, a total of64,215 women were
registered as newly diagnosed cases of cancer in situ. It is
possible to make a consistent and fairly accurate estimate of
the total influence in all birth cohorts of the screening
()
Li
3000 F
2000 F
'o00SCREENING FOR CERVIX CANCER 907
S.
a
o -
.I
a
c
8sor
2001
0
'Oi.!
Is 0za
3 > a
-
Z.
*400
.Ag
I
Figure 6 The total influence of screening measures taken up to
1981 when they have had their full effect, exemplified by the
cohort born in 1924-1928. For notations, see Figure 3.
measures regarding the number of diagnoses of invasive
cancer and deaths when the screening has had its full effect,
provided that no further screening measures were undertaken
after 1981. To do this, we require an estimate of the propor-
tion of screening detected (prevalent) in situ cases that with-
out therapeutic measures would have become invasive. This
proportion (Pprev) is not a constant - as the previously
reported one relating to all incident cases of in situ cancer
(Gustafsson & Adami, 1989)
- but a function of both age
and degree and timing of screening. Pprev was computed by
simulation to be on the average between 16.7 and 22.1% for
different 5-year birth cohorts. We will here use an overall
mean of 19.8% for Pprev.
The total reduction in reported invasive cervical cancers
due to screening measures undertaken up to 1981 will thus be
0.198 x 64,215 or about 12,700 cases. Likewise, the total
reduction of deaths can be calculated as: tot-scr x Pprex +.
Tot-scr is the total number of eliminated cases of cancer in
situ (64,215) and the parameter Q is the proportion of
patients with invasive cancer who will die from this disease,
which has been estimated at 33% (Gustafsson & Adami,
1989). According to this calculation, the screening up to 1981
will ultimately reduce the number of deaths from cancer of
the cervix by about 4,200.
On account of deaths from causes other than cervical
cancer between the time of detection of cancer in situ by
screening and the otherwise expected times of invasive diag-
nosis and death from cervical cancer respectively, the figures
mentioned above should be decreased by about 2% and 3%.
This will yield a total calculated reduction of cases of
invasive cancer by 12,500 and of deaths due to cervical
cancer by 4,100. To this latter effect of screening, we should
add that due to earlier detection of invasive cases.
Since the end of the 1960s, about 3,800 cases of cancer in
situ have been found each year. This implies an estimated
annual reduction in the number of cases of invasive cancer
by about 750 and of the number of deaths by about 250,
although these gains are spread forward over several years,
as shown in Figure 6. This also implies that one life will be
saved for every 16 cases of cancer in situ that are detected.
Discussion
The approaches used so far in various studies for evaluating
the effects of screening for cervical cancer have been aimed,
firstly, at finding qualitative evidence for its efficacy from
reported incidence and mortality data before and after imple-
mentation of screening programmes (Day, 1984; Hakama et
al., 1985; Pettersson et al., 1985); and, secondly, at estimating
quantitatively the relative and absolute reductions in invasive
cancer that can be achieved by different screening policies
(IARC, 1986; Lynge et al., 1990).
Our data further justify the conclusion that cytological
screening can reduce the incidence of invasive cervical cancer
and subsequently the mortality from this disease. This study
was carried out, however, from a fundamentally different
perspective. Detailed data on the natural history of cervical
neoplasia were first obtained by an identification technique.
By this means mutual consistency was achieved between
model structure, statistical data from the entire female
population, the parameters which characterise the progres-
sion of cervical neoplasia, and all the incidence and
prevalence functions (Gustafsson & Adami, 1989). We
thereby escaped the difficulties inherent in previous simula-
tion studies which required arbitrary assumptions about the
proportions and transition times that characterise the pro-
gression of cervical neoplasia to invasive cancer and death
(Hakama et al., 1985; Parkin & Moss, 1986). For instance,
the study by Parkin and Moss was based on a considerably
higher rate of progression and a shorter duration of the
preclinical phase (sojourn time) than that revealed by the
identification technique on Swedish data (Gustafsson &
Adami, 1989). We found the parameters (except the death
proportion) which describe this sequence of events to be
largely unrelated to the women's age, supporting a recent
finding that age does not affect the sensitivity of cytologic
screening or the detectable preclinical phase of the disease
(IARC, 1986).
Proceeding from the previously estimated parameters of
the natural history model and from reported incidence and
mortality statistics, we were able to elucidate by simulation
firstly the profound reduction in prevalence rates after
screening, and secondly the reduction up to 1981 in the
morbidity and mortality from invasive cancer of the cervix
for each birth cohort. The impact of screening was greatest
among the youngest cohorts - most women have been
invited every fourth year since the age of 30. It needs to be
emphasised, however, that the majority, about 75% of the
cytological smears were taken outside this organised screen-
ing programme (Pettersson et al., 1985; National Board of
Health and Welfare, 1982). The extent of exposure to this
diagnostic method has therefore most probably varied widely
within the population. Nevertheless, the maximal reduction
in the reported incidence of 60-70% in the most extensively
screened cohorts was remarkably similar to the recently
estimated figures of 70 and 82% after screening every 5 years
from ages 35 and 25, respectively (IARC, 1986). Incomplete
coverage of the target population, and the fact that screening
had not yet achieved its maximal effect might explain at least
part of the difference. Our results thus support the favour-
able estimates derived from the international collaborative
study (IARC, 1986) and indicate that simulation experiments
based on a model of the natural history might provide
supplementary information concerning the outcome of differ-
ent screening strategies.
The transition times from a detectable in situ stage via
clinical diagnosis of invasive cancer to death are long; the
entire sequence of events has an average duration of about
18-20 years (Gustafsson & Adami, 1989). The ultimate
effects of certain screening measures are accordingly
dispersed in time over a number of years. Simulation
experiments enabled us to predict the entire future gain in
terms of reduction in the reported incidence and mortality, as
illustrated in Figure 6. The disturbance of the system clearly
has a complex dynamic which will last for several decades
after cessation of the screening measures. The most impor-
tant future implication of this technique lies in simulation
runs whereby the entire gain from different screening
strategies can be calculated and its dispersion in time can be
foreseen.
The last approach described in the Results section, namely
direct calculation of the total reduction in incidence and
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mortality from the parameter estimates, can be applied to
other populations, provided that the natural history has ap-
proximately the same characteristics. By such means, it
would be possible to evaluate the cost-benefit and the cost-
effectiveness of different screening programmes. In addition,
this approach puts the value of revealing an in situ cancer at
screening into an individual perspective. Prevention of
invasive cancer is the primary goal in that context. A pro-
gression rate of around 20% among in situ cases detected at
screening implies that overtreatment of about four women
with cancer in situ is the price to be paid for escaping one
case of invasive cancer. The use of death due to cancer of the
cervix as an end-point would increase the extent of overtreat-
ment to about 15 women out of 16.
A considerable extent of overtreatment is obviously an
inherent feature of screening methods aimed at detecting
premalignant lesions that do not regularly progress at
invasive cancer. The possible somatic and psychological mor-
bidity involved in the diagnosis and treatment of even pre-
invasive cancer in large groups of women requires attention.
Reliable information on such consequences needs to be taken
into account when we proceed from the tentatively designed
screening efforts of yesterday to the scientifically founded
ones of the future.
This study was supported by grants from the Swedish Cancer
Society.
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